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Abstract: The gut microbiota is extremely important for the health of the host across its lifespan.
Recent studies have elucidated connections between the gut microbiota and neurological disease
and disorders such as depression, anxiety, Alzheimer’s disease (AD), autism, and a host of other
brain illnesses. Dysbiosis of the normal gut flora can have negative consequences for humans,
especially throughout key periods during our lifespan as the gut microbes change with age in both
phenotype and number of bacterial species. Neurologic diseases, mental disorders, and euthymic
states are influenced by alterations in the metabolites produced by gut microbial milieu. We introduce
a new concept, namely, the mycobiota and microbiota-gut-brain neuroendocrine axis and discuss
co-metabolism with emphasis on means to influence or correct disruptions to normal gut flora
throughout the lifespan from early development to old age. These changes involve inflammation and
involve the permeability of barriers, such as the intestine blood barrier, the blood–brain barrier, and
others. The mycobiota and microbiota–gut–brain axis offer new research horizons and represents
a great potential target for new therapeutics, including approaches based around inflammatory
disruptive process, genetically engineered drug delivery systems, diseased cell culling “kill switches”,
phage-like therapies, medicinal chemistry, or microbial parabiosis to name a few.
Keywords: aging; microbiota; mycobiota; gut-brain-axis; CRISPR; blood–brain barrier; leaky gut; leaky
brain; autism; schizophrenia; transsulfuration; synbiotics; parkinson disease; Alzheimer’s disease
1. Introduction
The human body exists in symbiosis with microbial communities on the skin, in the oral mucosa,
vaginal mucosa, and in the gut [1]. The symbiotic relationship between the intestinal microbiota and
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gut immunity implies the necessity to keep constant gut surveillance controlling for excessive bacterial
load and limiting pathogens. Changes in the abundance and type of organisms comprising the fecal
microbiota extends beyond simple commensalism to influence health and disease through a wide
variety of pathologies, which includes neurodegenerative disorders, digestive disease, hepatic diseases,
diabetes, and viral infections [2–6].
Metagenomic studies have elucidated reductions in the richness of microbial genes and alterations
to the functional capabilities of the fecal microbiota [7] leading to hallmarks of obesity, liver disease,
and type II diabetes, which can be modified by dietary interventions [8,9]. The gut microbiome harbors
over 150 times more genes than the human genome, which significantly increases the repertoire of
functional genes possibly available to the host and contributes to system energy from food and energy
harvesting from substrates that are indigestible by humans without bacterial digestive enzymes.
1.1. Relationship between the Brain and the Gut Microbiota
The gut microbiota is comprised of many diverse organisms each with their own niche in the
gut. While each different grouping of bacteria has its own role in the gut, all the organisms in the
gut flora produce metabolites and small molecules that can either have negative or positive impacts
on host health [1]. The intestinal microbiome is colonized by organisms from the Firmicutes and
Actinobacteria (Gram-positive), as well as Proteobacteria and Bacteroidetes (Gram-negative). However,
in healthy individuals the majority of the gut is colonized by Firmicutes and Bacteroidetes. The gut
flora produces small molecule metabolites including 40 known neurotransmitters, such as dopamine,
serotonin, and GABA (gamma-aminobutyric acid, an inhibitory neurotransmitter). Typical roles of the
gut flora include metabolizing nutrients such as plant phenols, sugars, and bile salts [2].
The metabolites and small molecule products produced by the gut flora are of extreme interest in
the chemical signaling pathway called co-metabolism between the gut microbiota and the brain, named
as the Microbiota–Gut–Brain (MGB) axis. Microbiota of the gut and the brain work in conjunction
to promote proper function of the central nervous system. In healthy individuals, the relationship
between the host and the gut microbiota is mutually beneficial, however, this relationship can be
disrupted by the introduction of pathogenic bacteria, viruses, fungi, and other parasites. This ultimately
leads to disruptions in the MGB axis and could have negative consequences on the mental health of
the host. Change in the normal gut flora of the host can be attributed to a variety of different events:
dietary changes, lifestyle changes, and antibiotic intervention [1]. Commensal bacteria in the gut work
in conjunction with lymphoid tissues that are associated with the gut, to form a tight relationship
between cognitive behavior and the gut microbiota [1,3]. Changes to the gut flora have an indirect
impact on the behavior and brain physiology via metabolic signaling from the gut to the brain [1,3].
Intestinal microbiota have significant influence over the biochemistry of the host via production of
hormones that can alter neurobiology [2]. This can influence the severity of diseases such as autism,
Alzheimer’s disease, Parkinson’s disease, depression, anxiety, and a host of other mental disorders
and diseases [2]. A healthy balanced gut microbiota is extremely important not only for the digestive
system health, but also for mental and general health.
1.2. Blood Barriers and Their Roles in the MGB Axis
1.2.1. Intestinal Blood Barrier
The intestinal blood barrier has two primary functions: first, is to act as a physical barrier to
prevent the passage of harmful metabolites, microorganisms, and microbial toxins from getting into the
blood stream; second, the intestinal blood barrier acts as a selectively permeable membrane to allow
the transport of beneficial metabolites from the gut lumen to the blood stream [10]. Epithelial cells
form a protective monolayer in order to mediate the barrier permeability. This epithelial monolayer is
held together at the connecting edges of the epithelial cells by a host of connective proteins that form
junctions. The three main junctions responsible for maintaining permeability are the desmosomes,
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tight junctions, and adherens junctions [10]. Tight junctions are on the apical side of the epithelial
cell and are comprised of claudin binding and dimerization, which are mediated by adaptor proteins
known as zona occludins. Another major protein player in this junction is the occludin proteins that
also help mediate strong binding at this junction [10]. The major function of the tight junction is to seal
the apical side gap between neighboring epithelial cells [10]. Adherens junctions are located more
basal than the tight junctions, however, are not completely on the basal side of the membrane [10].
Adherens junctions are a cellular anchoring system that is used to connect the actin filaments of one
cell to its neighboring cells [11]. Adherens junctions utilize several adaptor proteins to mediate the
hemophilic binding of classical cadherins, such as E-cadherin [10]. These adaptor proteins, including:
p120, β-catenin, and α-catenin, function to connect the F-actin filaments within neighboring cells to
the cadherins in the extracellular space [10]. Desmosomes utilize non-classical cadherins (desmoglein
and desmocollin) in conjunction with adaptor proteins (plakoglobin and plakophilin) to interact with
intermediate filaments [11]. The primary function of the desmosome is to connect the intermediate
filaments of neighboring cells to provide the extra strength and support to the epithelial layer [11].
There are two mechanisms for transport across the intestinal blood barrier: first is transcellular,
and second is the paracellular pathway. In the transcellular pathway, solutes from the gut pass through
the epithelial cells directly [10]. Transporters for different small molecules and metabolites produced
in the gut are spread throughout the apical membrane of the epithelial layer [11]. This allows for
the intake of the metabolites into the epithelial cells, which are then trafficked to the basal side of
the epithelial cell and are deposited into circulation [11]. Paracellular transport of metabolites occurs
in the extracellular space between epithelial cells [10]. This paracellular pathway is intracellularly
regulated by cytosolic adaptor proteins as well as the formation of pores [10,11]. Specifically, for tight
junctions, the claudins comprising the tight junctions are believed to form pores to selectively allow
certain metabolites to pass [11]. Dysregulation of these different permeability pathways can lead to
“leaky gut” diseases, such as celiac disease [10].
1.2.2. Blood–Brain Barrier
For the blood–brain barrier, endothelial cells line the microvasculature and act as a highly
selectively permeable barrier to prevent most metabolites and small molecules from passing through to
the brain [12]. Due to the high selectivity of this barrier, the transcellular and paracellular permeability’s
are highly regulated and generally controlled by two transporters, the efflux transporters and the
nutrient transporters [12]. Similarly, the intestinal blood barrier there are cell adhesion junctions that
connect the endothelial neighboring cells together, including the tight junctions, adherens junctions,
and the desmosomes. Dysregulation of the transport of metabolites and small molecules across the
blood–brain barrier can lead to a host of neurological diseases by losing selectivity or degradation of
the barrier [12]. This would suggest a correlation to “leaky brain” disorders.
Blood barriers are associated with most tissues and are a mucosal layer that prevents trafficking
of large molecules, some small molecules, and bacteria across the permeable layer into the blood or
other compartments. Two important permeable barriers involved with the microbiota–gut brain axis
are the intestinal–blood barrier (IBB) and the blood–brain barrier (BBB). Disruptions of the normal
function of these protective barriers has been attributed to a syndrome known as “leaky syndrome” [1].
Leaky syndrome has been associated with the gut in previous studies showing that dysbiosis leads to
an increased permeability of the IBB, which allows bacteria and small molecule metabolites produced
in the gut to travel to distal organs via the bloodstream [1]. In combination with leaky gut, leaky brain
could lead to potential negative neurological consequences such as increased severity of depression,
anxiety, or a host of neurological diseases [1]. Dysbiosis was shown to mediate increased permeability
of the blood–brain barrier and the blood intestine barrier, which allows metabolites and hormones to
more readily pass and leave the gut (IBB) as well as enter the brain (BBB) and alter the biochemical
homeostasis of the brain [1]. The disruption of these barriers could be the result of cytokine stress,
inflammation, or alterations to the gut flora [1].
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The breakdown of the intestinal blood barrier has previously been shown to be a causative
mechanism of “leaky gut” syndromes, such as celiac disease [1]. Similarly, recent studies have linked the
breakdown of the blood–brain barrier to neuropathological conditions, such as Alzheimer’s disease [13].
As with “leaky gut” based syndromes, which are due to increased permeability of the intestinal–blood
barrier, there is new evidence that this barrier breach can lead to brain pathology and the potential
to become “leaky brain” conditions. A recent study implemented the use of a new cerebrospinal
fluid biomarker to better understand the role of blood–brain barrier degradation in neuropathological
diseases and disorders [13]. Through a combined use of this novel cerebrospinal fluid biomarker
and magnetic resonance imaging, the investigators were able to elucidate the relationship between
amyloid β and tau biomarkers (classical biomarkers of Alzheimer’s disease) and the breakdown of the
blood–brain barrier [13]. In patients exhibiting early cognitive dysfunction there is a degradation of the
blood–brain barrier combined with damage of the capillaries within the brain that occurs independently
of the development of amyloid β or tau [13]. This indicates the potential importance of the detection
of the blood–brain barrier integrity as a biomarker in the early diagnostics of neuropathologies,
such as Alzheimer’s disease [13]. Patients could be diagnosed with a neuropathological conditions
before developing clinical manifestations or the production of disease state proteins [13]. While most
neuropathologies are do not form as a result of the blood–brain barrier degradation, “leaky brain”
has the potential to exacerbate onset of neuropathologies.
1.3. MGB Axis: A New and Important Drug Target
As more knowledge of the relationship between the gut microbiota and the brain are uncovered,
research focuses can begin to shift allowing these pathways to be used tohelp patients with neurological
and psychiatric disorders. Antibiotic interventions are very disruptive for the gut flora and lead to
dysbiosis, which can impact the metabolites produced in the gut [2,5]. This could ultimately have
negative consequences for patients with an infection that also have depression, anxiety, or another
mental disorder due to alterations of gut produced metabolites and hormones [14]. New methods are
needed for treating patients while protecting their microbiota.
One suggested method would be to engineer a genetic kill switch into the gut flora [2], this could
be given to the patient via a probiotic and allowed to colonize the gut to aid in normal flora colonization.
This approach could be useful in killing select members of the gut flora so as not to alter the chemical
signaling between the brain and the gut, whilst still being able to clear the infection. An advantage of
this approach would be that it would maintain the integrity of the host tissue [2]. Phage therapy is
another strategythat could be effective for managing bacterial infections in the gut without altering the
metabolites produced [5]. This approach utilizes a bacteriophage or bioagent produced by the phage
to target and kill specific bacteria [5]. This technique utilizes a modified phage that is non-replicative
and then the live phage is given orally to target the gastrointestinal infection [5]. Bacteriophages and
bacteriosins in particular have a very narrow targeting range and therefore their lytic activity will not
affect the normal gut flora or the host. Non-phage engineered approaches such as non-reproducing
avidocins or bacteriosins, may offer superior utility and be able to safely eradicate infectious pathogens
from food or hospitals without irradiation or harmful chemicals [15]. This method has advantages
over phage technology due to its specificity for the bacteria and a non-lytic cycle.
1.4. The Mycobiota and Microbiota across the Lifespan
In embryonic, early development and prenatal and post-natal nutrition, the mycobiome and the
microbiome, which encompasses many bacteria, are a key piece of the puzzle influencing metabolism,
development, immunity, and behavior [16–18]. Not only do we still need to determine how much of
the microbiome is fungi but we also need to better understand the types and their role among the other
organisms. The mycobiome appear to be part of the rarer biosphere, which is poorly characterized [19].
It is still unclear how fungi influence the other members of the microbiome community and what
influence they have. However, it is clear that fungi are becoming more of a threat as a cause of
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multi-drug resistant infections and pandemics. Therefore, it is important that we seek to understand
their role not only within the environment but also within ourselves.
In addition, as we dynamically change the environment leading to microbiome evolution there is
a renewed importance to understanding the mycobiome as we manipulate our own immune systems
making the commensal species residing in the environment and our bodies a possible threat to our
survival [20]. There is always a balance between the good and bad but any perturbation can tip the
scales in favor of pathogenicity over symbiosis. Certainly, we live among fungal threats when we
become immune compromised, have increased inflammation, or underlying defects that compromise
our natural defenses. Fungi represent a challenge to detect and classify as well as to determine
susceptibilities of and represent a growing threat in the wave of anti-microbial resistance [8].
Much work has been done on bacteria that effects early development but we are still working on
understanding the fungal species that make up these diverse interactions. More work is needed to
understand the origin of our fungal mycobiome and the way it changes and evolves as we age [20,21].
Fungal pathogenesis seems to be the most threatening at the beginning and end of life when we are
most vulnerable. Likely, both overgrowth and perhaps undergrowth of these species cause related
pathogenesis. The question still remains if there is benefit to establishing or re-establishing a mycobiome
with pro-fungal agents. In addition, we ask what the impact of anti-microbial or anti-viral agents on
this system could be.
One approach is to consider routes of infection within the nervous system, such as those from
blood-borne infections with Candida albicans, which is an increasingly recognized modern problem
and may help explain increased proliferation and age-related activation of microglia and astrocytes
in neurodegeneration and aging [21,22]. Further, it was recently shown by Nation et al., that a leaky
blood–brain barrier and barrier breakdown is an early marker of cognitive dysfunction in humans [13].
Mouse models of low-grade candidemia have been used to monitor the effect of disseminated infection
on cerebral function and relevant immune determinants. C. albicans yeast cells were found to directly
cause a highly localized cerebritis marked by the accumulation of activated astroglia and microglia [23].
One protective mechanism seemed to involve Amyloid beta protein precursor which accumulates
around granulomas, while cleaved amyloid beta (Aβ) peptide formation and deposition was found in
this model. This group also showed CNS (central nervous system)-localized C. albicans was involved
in transactivation of NF-κB and induced downstream production of interleukin-1β (IL-1β), IL-6,
and tumor necrosis factor (TNF) [23]. Finally, mice infected with C. albicans display mild memory
impairment that appeared to resolve with clearance of the fungal infection.
To find fungal elements we have to explore the natural reservoirs of where we find myco-organisms
in the body such as gastrointestinal, respiratory, and reproductive systems. In addition, there is a
constant push and pull between the pathogenic and non-pathogenic myco-organisms that exist both
in our bodies and in the environment. These are affected not only by the general state of health but
also factors like demographics, racial, ethnic, and gender differences [24]. Attempts to classify our
fungal mycobiome, show a unique signature reflective of the individual, almost like a fingerprint.
Differences in the host innate immunity as noted by Ghannoum et al., causesalterations in the oral
fungal mycobiome between HIV positive and negative individuals as well asstudies involving the
lung mycobiome between healthy and transplant patients [25].
There is evidence that the mycobiome may counteract some of the pathogenic species in our gut
like Clostridioides difficle. Some studies suggest that the fungi compete with these pathogenic species and
perhaps even mitigate their potential for harm [26]. Despite many studies about the vaginal microbiome,
the fungal profile remains to be fully characterized [27,28]. There is much to learn about the mycobiome
including its beginning in early life as well as its influence with inflammation and host immunity.
Most of the research to date involves Candida albicans colonization. However, other endemic
fungi like Histoplasma or Aspergillus are less likely to colonize and more likely to causedisease. Some
organisms like Cryptococcus or Pneumocystis can co-exist within our bodies until we have a change
in our immune system. Saccharomyces cerevisiae var. boulardii are considered the good fungi used in
Biomedicines 2019, 7, 24 6 of 21
probiotics. There are different sites of the human body that serve as sites of colonization or reservoirs
for fungi. Candida, in particular, has found many niches in the body. It has been shown to survive on
both living surfaces as well as artificial devices via its ability to form biofilms and adapt to its host [29].
It is still unclear how it can transition from a component of the mycobiometo a pathogenic threat. This is
undoubtedly affected by antibiotic resistance pressures, increased immune suppression in hosts, use of
medical devices and prosthesis and other factors. These threats have issues in antifungal resistance in
the form of species like Candida auris. No doubt there is a role for fungus in the inflammatory cascade,
immune regulation, metabolism, and, in particular, the healthymycobiome.
Likely, it may all start in our developing gut which is known to be affected by the type of delivery
(vaginal versus cesarean), feeding (breast versus formula), antibiotics, environment, and gestational
age. It is believed that the placenta mycobiome could be involved in immune responses impacting
fetal immune system development, the course of maternal pregnancy and even future health outcomes
for the newborn like diabetes and obesity [30]. Today, we seek to repair this dysbiosis by using pre-
and pro-biotics together as synbiotics to repair the gut. We now know that no part of our development
is truly sterile, even the womb, there are both inflammatory and infectious components that lead to
outcomes like prematurity [31].
The role of the fetal intestine in both intra and extra uterine growth is still being explored. As it
seems that pregnancy is really the initial exposure that the fetus has to the micro and thus, mycobiome,
it may be possible to intervene in this development by dietary alterations in the mother such as the
addition of certain additives to the diet [32]. Just how these relevant fungi are transmitted and how they
remain colonized appears to be unclear (e.g., amniotic fluid exposure, method of delivery, and breast
milk exposure) and more research needs to be done in this regard. The effects of these organisms can
possibly explain the common complications of pregnancy such as pre-term labor or other inflammatory
processes, as suggested by Neu et al. [33]. They may also extend their effects into the autoimmune
life of the infant and adult, however, this has not been proven yet. Neu suggests that “the microbial
metabolites and immunologic responses in mothers’ gastrointestinal tracts and genitourinary systems
and mouth may have profound effects on the fetus.” Other relevant factors include method of feeding,
exposure to antibiotics, as well as gastric acid exposure [33].
One particular area of interest includes the possible ongoing exposure to mother’s milk that
breast-fed babies have as their sole dietary intake for at least 4-6 months of their life. It could be that
this milk, which contains maternal bacteria and fungi, helps to build the micro and mycobiome of the
growing baby [34]. As Thum et al. note, this dynamic environment may be altered by multiple factors,
such as antibiotic exposure, allergens, and illnesses [32]. In addition, even less is known about the
transfer of fungi to the infant.
While it is frequently noted that breast milk is tailored to fit the needs of the infant, in a broader
context, this could be interpreted as reflective of the maternal micro and mycobiome that is laid out
specifically for her infant to help the infant survive and thrive in their external environment [35].
As Neu points out, the ramifications of the “milk microbiome” and in addition the milk mycobiome
has yet to be fully explored [33]. In fact, Ward et al. did a study to characterize the skin, oral, and anal
mycobiomes in 17 infants as well as the anal and vaginal mycobiomes of their moms by internal
transcribed spacer 2 (ITS2) amplicon sequencing demonstrating that they differed by body site, mode
of birthing and challenges the idea that transmission is exclusively vertical or sequential and not
otherwise environmental (See Table A1 in the Appendix A) [36]. Ultimately, more studies are needed
to evaluate the evolution and characteristics of our fungal mycobiome [37].
1.5. Autism and ASD in Relation to the Microbiota and Child Development
Once weaned a child’s microbiota is stabilized towards an adult-type phylogenetic architecture
and remains relatively stable throughout adulthood [3,6]. Due to the stable phylogenic persistence
through adulthood our focus switches from the phylogenic architecture to dysbiosis [38]. Instead,
we consider aberrant ecosystems and their associated diseases, as compared to unaffected individuals.
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The gut microbiota is increasingly implicated in the etiology of two common childhood developmental
brain disorders, autism and autistic spectrum disorder (ASD). Although considerable conjecture centers
on the pathobiology, one target is the microbiota–gut–brain axis [38–40]. The etiology of these broad
spectrum disorders is unclear, but genetic and environmental factors play a role in their pathogenesis.
It has been shown that maternal infection, the stresses of pregnancy, and a host of prenatal insults
may increase the risk for neuro-developmental disorders later in life, such as schizophrenia, autism,
or other cognitive and behavioral syndromes.
Several gastrointestinal abnormalities and high rates of antibiotic use are linked to microbial
composition and contribute to the alteration of function found in ASD and autism-affected
individuals [41–43]. In an ASD mouse model, studies under germ-free conditions show reproducible
social deficits and increases in repetitive behaviors similar to those observed in ASD [44] and behavior
traits that are autism-like. GI (gastrointestinal) phenotypes are also associated with altered microbiota
and histone modification as well [40,45].
Many studies, support a role for the gut microbiota in the formation of the potential
neuro-modulatory metabolite of phenylalanine and tyrosine, 3-(3-hydroxyphenyl) 3-hydroxypropionic
acid (3-HPHPA) and possibly 4-(3-hydroxyphenyl) 3-hydroxypropionic acid (4-HPHPA), and others
are involved in the pathogenesis of ASD, autism, dysbiosis, schizophrenia, and detected in human
and rodent urine [46–50]. The psychobiotics, defined as probiotics that may improve psychiatric,
or neurological illnesses supports a mechanism for autism and schizophrenia assertions. For example,
a probiotic consisting of Bacteroides fragilis was given in early adolescence, which ameliorated some
behavioral deficits in a rodent autism model [51–53]. Shaw et al, has made the assertion that several
Clostridia bacterial species are at the heart of the schizophrenia and autism connection [48]. Our team
recently reported this marker (HPHPA) in human CSF (cereberal spinofluid, serum, and in urine [50],
confirmed by previous studies [54,55].
1.6. Consequences to Perturbation in the Gut Microbiota
We argue that any factor that modulates the microbiota, such as antibiotic use, stress, disease or
anything that prevents a child from receiving microbial aliquots from the mother, even during birth,
can lead to permeability of the blood–brain barrier after birth and likely affect the transmission of
virulence factors, pathogens or deleterious metabolites for an undetermined length of time. Besides
metabolic disorders like obesity and gastrointestinal disorders like inflammatory bowel disease and
irritable bowel syndrome, altered microbiota have also been linked to neuropsychological disorders
such as depression and ASD [56]. Although it has been postulated, it is not well established that these
factors indeed contribute to disease pathogenesis, in cases with autism, ASD or schizophrenia, and it
remains to be determined. While the degree to which intestinal microbiota affects dietary preference is
not well defined; the converse is evident in that diet can rapidly change the microbiome [57].
1.7. Aging and the Microbiota through the Lifespan
In healthy individuals the normal gut flora is composed primarily of members of the Firmicutes,
however, other phyla including Bacteroidetes, Proteobacteria, and Actinobacteria, which combined
with the Firmicutes comprise approximately 90 percent of the gut flora [58]. Microbial phylogenic
architecture with aging has large inter-individual variability [4,7] and reduced biodiversity in older
individuals, which compromises microbiota stability compared to younger individuals [4]. Over the
course of the human lifespan, shifts in the diversity and abundance of the different phlya occur in
response to factors such as diet, infections and other related factors (See Table A2 in Appendix A).
While dietary habits, can play an important role the question is whether inflammation plays a more
significant role. Aging is characterized by immunosenescence and thymus involution, which results
in the loss of T-cell education and functional deterioration of the neuro-immune system [59]. Aging
affects the human gut microbiota in several ways, namely, changes in the composition of metabolic
byproducts derived from host microbiota and mycobiota, changes in the phylogenetic composition,
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and interaction with the immune system [60]. These changes are associated with immunosenescence
and inflammatory aging and the age-related diseases associated with these processes. Bacterial and
fungal infections like blood-borne infections with yeast such as C. albicans are an increasing problem,
with age and may be concomitant with immunosenescence [61,62].
We speculate that yeasts could be involved in chronic neurodegenerative disorders, for example,
plaques in mice resemble senile plaques of Alzheimer’s disease (AD) patients. Previous studies found
that yeasts are commonly found in the brains of AD patients. Yeast deploy a mechanism to avoid the
usual defenses, especially the blood–brain barrier, that produce immunologic defense mechanisms
causing cytokine stress, down-regulation of inflammation associated genes, and improvement in
colonic mucosal conditions. Novel new probiotics could be used in the promotion of longevity and
prevention of immunosenescence. They offer new targets and treatment strategies for improving the
health of older individuals who already may be immunocompromised. In this context, the delivery of
probiotics and prebiotics or synbiotics may be useful for both prevention and treatment of age-related
pathobiologic conditions from the improvement of immune function to the maintenance of the integrity
of the gut barrier function, and the down-stream blood–brain barrier function [63] prevent most
infectious organisms from entering the brain, particularly the parenchyma [1].
1.8. The Promise of Fecal Transfer from Young Donors to Old-Aged Recipients
Microbial populations reveal significant change in several spheres of aging, and that gut microbes
have a significant influence on the health of the elderly [60]. In that regard, a novel target first
identified by aquatic researchers involves delivering gut microbes from young killifish to older
killifish thus extending the life span of the older fish, which is analogous to vertebrate parabiosis
where specific changes that occur between two animals sharing a circulatory system will reverse
some aging parameters in the older animal. How this finding in the short-lived African turquoise
killifish (Nothobranchius furzeri) extrapolates to mechanisms of higher vertebrates is still unclear [64].
Analogously, we have established protocols for fecal transplant though anaerobic encapsulation of
lyophilized material [65]. It may be as simple as repopulating appropriate commensal species or a
“eumicrobiota” to coin a concept, but a better understanding could help the elderly by imparting
beneficial metabolites and a helpful second genomic contribution within us all.
This work is reminiscent of older parabiosis experiments in rodents where young and older
animals are conjoined through a common circulatory system [66–68]. The autors of the work [60]
show interventions in this distantly related vertebrate model using microbiota from young did prevent
decreases in species diversity associated with aging and maintained a phenotypically younger gut
bacterial community. These authors characterized the young phenotype as overrepresentation of
Exiguobacterium, Planococcus, Propionigenium, and Psychrobacter [60].
The effect of the aforementioned process, which we have used in human transplant [65] was
long-lasting and systemic with beneficial effects including extended life span in this vertebrate model.
One often-overlooked research area, concerning the elderly and microbiota, is the significance of
microbial co-metabolism on drug efficacy or toxicity involving bacterial enzymatic activity and drug
metabolism [2]. This is especially important for personalized medicine and the need for a new
physiology of the elderly, who often use multiple drugs for extended periods of time compared
to the young. The microbiota-drug interaction will likely involve manipulating the mammalian
gut microbiome to enhance health, such as producing a pro-drug or vitamin that can reverse
age-related damage to DNA or aid cellular repair mechanisms from DNA damage, such as nicotinamide
mononucleotide (NMN).
Mice administered NMN were found to live 20 percent longer and were able to run faster than
the age matched control cohort [69]. Moreover, cells were indistinguishable from the young mice
in all respects except for repair findings. There are already a great many ways to influence the gut
microbiome, including calorie restriction, and the observed impact of these strategies puts some
limits on what it is plausible to expect from a more rigorous, informed, and technologically assisted
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adjustment of the microbial population. Species with short lifespans also have a much greater plasticity
of longevity compared to humans in interventions of this manner. The method of calorie restriction
that increased the life span of mice by 40 percent are not nearly as effective or beneficial in humans.
1.9. Methionine Cycle Genes Contribute to Epigenetic Regulation
Bacteria could provide missing enzymes and correct genetic mutations in metabolism, such as the
common methylenetetrahydrofolate reductase gene (MTHFR) Genetic polymorphisms in the MTHFR
gene results in low methionine production and high homocysteine (HCys) levels, which in turn may
lead to accumulation of S-adenosylhomocysteine (SAH) and low levels of S-adenosylmethionine (SAM)
in humans where homocysteine contributes to cardiovascular disease and hyperhomocysteinemia
induces oxidative stress. MTHFR is important to the methionine cycle and transsulfuration pathway
that regulate SAM, an important methyl donor for histone methyltransferases (HMTs) and DNA
methyltransferases (DNMTs) [70]. Mutations in the MTHFR gene produce low levels of SAM and
the MTHFR enzyme reduces 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, necessary
for the transference of a methyl group to the methionine [70]. Low levels of SAM can affect global
DNA and histone hypomethylation in part through hyperhomocysteinemia, making this treatment an
important possible means to affect epigenetics via modulation of nutrient or vitamin cofactor uptake.
Analogous to NMN for DNA repair, H2S, a significant bacteria-derived gaseous water and lipid
soluble signaling mediator, could be used to protect cells from oxidative stress and ischemia-reperfusion
and other insult. Similar to nitric oxide or carbon monoxide, H2S plays a role in both physiologic and
pathophysiologic mechanisms from regulation of synaptic transmission, to inflammation, vascular
tone maintenance and angiogenesis for vascular conditions. Further, the hydrogen sulfide pathway is
involved in cancer and could be a suitable treatment target or be developed as a drug or drug delivery
vehicle through novel probiotics. Using bacterial biosynthetic machinery, we could envision dietary
l-methionine, l-cysteine, and the cofactor pyridoxal-5′-phosphate to produce H2S in tissues or the
gut for therapeutic purposes. Deficiencies would be the first issue to correct through dietary means,
such as those involving the transsulfuration pathway and increasing the synthesis of glutathione
(GSH) [71]. Arguably, GSH is the most significant mammalian non-enzymatic antioxidant, especially
important for de-poisoning the host from mercury contamination, without use of questionable chelation
therapy approaches.
Outside of affecting nutritional deficiencies or medical conditions that are due in part to gut
pathogen dysbiosis, it seems unlikely that large gains in the human lifespan are going to be realized.
However, the deleterious aspects of aging may be slowed or even partly reversed with these approaches
if enough translational funding opportunities become available. We could certainly expect an improved
quality of life and maybe a longer health-span from these technologies. In this regard, a few concepts
should be mentioned starting with Caleb “Tuck” Finch’s idea of negligible senescence, which was
further refined by Aubrey de Grey as Strategies for Engineered Negligible Senescence (SENS), aimed
at developing a better understanding or even “cure” for aging [72]. Perhaps the rate of achieving these
strategies would be hastened though the microbiota and its tremendous potential for revolutionary
transformation. This new approach will likely culminate in novel therapies and technologies capable
of repairing the known and future forms of accumulated cellular and molecular age-related damage.
Finally, the apparent low-hanging fruit on the vine of science would involve using typed and
cross-matched synbiotics as a novel “new drug”. This concept is best illustrated by a recent case where
a woman of relatively normal weight with Clostridioides difficile infection, was successfully treated with
a fecal transplant with widely different gut bacteria while concurrenty experiencing rapid weight gain
of about 50 pounds [73]. The authors did not offer a hypothesis for the mechanisms of transmission nor
identify and sequence the species involved over the course of the treatment of the obese phenotype,
thus not demonstrating a clear causal relationship in this case. Nevertheless, it is inferred that the
microbiota plays an important role in weight gain [74,75] and could help in treating obesity, diabetes,
heart disease, and a host of other common illnesses.
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1.10. CRISPR and Gene Engineering Prospects
A newer approach for the transformative potential of the microbiota comes from clustered
regularly interspaced short palindromic repeats (CRISPR), which was first identified in bacteria and
function as a prokaryotic immune mechanism to bacteriophage infection. Instances of viral infection
are met with Cas cleavage of phage DNA which is reintroduced to the bacterial genome at the CRISPR
loci as spacer regions flanked by palindromic repeats. This natural bacterial defense mechanism
has been engineered to become a powerful genome editing tool using synthetic guide RNA to allow
sequence specific nuclease activity. The use of short RNA guides differentiates it from other synthetic
biological techniques, namely transcription activator-like effector nucleases (TALENs) and zinc finger
nucleases (ZFN). The latter rely on specifically engineered DNA binding domains that are limited to the
single set of nucleic acid sequences they are designed for, but are prone to off-target mutagenesis [76].
In contrast, the more easily synthesized and interchanged CRISPR RNA (crRNAs) guides afford
the CRISPR-Cas system greater versatility and flexibility, especially when multiple modifications of
many different genomes is desired. The use of multiple recognition sequences on single crRNAs
allow simultaneous editing of multiple sequences of interest [77]. Additionally, nuclease-null Cas9 can
similarly bind crRNA and recognize target sequences without excising DNA, allowing it to regulate
transcriptional activity, function as nucleic acid tethers, labeling molecules, and DNA scaffolding. This
affords CRISPR genetic manipulation powerful control over bacterial genes and metabolism through
target translational activation and inhibition [78].
The development of CRISPR-Cas as a genetic engineering tool has been paralleled by growing
understanding of the human microbiome and its far-reaching consequences for human physical and
mental health. Modern dietary and environmental factors can have disrupting influences on the
microbiome and by proxy, health outcomes. Medications and dietary habits have been shown to cause
changes in populations of microbiota [79].
Studies of humanized mice demonstrate the detrimental effect these diets have on gut biodiversity.
While fecal transplants are effective in restoring normal populations of microbiota, continued
consumption of low fiber and high carbohydrate foods will cause repeated dysbiosis in many
gut microbes. Barring population wide dietary changes towards high fiber and complex starch foods,
it may simply be more feasible to engineer bacteria prone to decline under these conditions using
CRISPR to enable microbiota to better adapt to our modern dietary and pharmacological environments.
CRISPR inhibition (CRISPRi) and activation (CRISPRa) have been used to modulate bacterial
genetic expression. Here, designing is particularly useful for genes encoding bacterial pathogenic
factors, such as biofilm formation and toxin eradication. CRISPRi has been used to inhibit transcription
of mRFP in E. ecoli through horizontal gene transfer of plasmid containing dCas9 and appropriate
short guide RNA (sgRNA) [80]. Similar techniques were employed to synthesize sgRNA targeting the
E. coli luxS gene which encodes for a synthase involved in AI-2 which guides biofilm formation [81].
In principle, given appropriate sgRNA and delivery, any gene of interest can be subject to CRISPR
activation or inactivation.
Neurodegenerative diseases such as Parkinson disease (PD) and Alzheimer’s disease are associated
with dysbiosis of microbiota in a bidirectional relationship typical of the gut–brain axis [82]. Microbiota
are critical in producing signal molecules and hormones from the intestinal metabolism which can
affect neurological disease states and central nervous system inflammation. Additionally, disruption of
the microbiome can further propagate neurodegenerative disease pathobiology [83,84]. With PD and
AD signaling effector molecules, in the microbiome are an important for understanding mechanisms
underlying disease pathogenesis and using the microbiota is one targeting approach for potential
treatments for these disorders.
As discussed, CRISPR allows for influence over bacterial metabolism through either modification
of whole genes, or nuclease lacking CRISPRi/CRISPRa binding to target genes in order to effect
gene expression without sequence modification. Genetic manipulation, especially with respect
to bacterial metabolism, signal molecule production, and hormonal secretion can offer a much
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more direct approach to influencing CNS inflammation, especially as a result of dysbiosis found in
neurodegenerative disorders.
Prebiotics, such as, short chain fatty acids (SCFAs), are a bacterial metabolite of particular
importance as they act as both signaling molecules and provide available energy from otherwise
indigestible carbohydrates, and play a role in maintaining intestinal cell layer integrity [1,85]. SCFAs
act as signal molecules and have regulatory effects on G-protein-coupled receptors (GPCRs) and histone
deacetylation (HDAC). GPCRs, their cognate kinases and HDACs are implicated in the pathogenesis of
neurodegenerative diseases [86,87]. Among other signaling effects, SFCAs modulate immune responses
by activating GCPRs, which is a very common drug target, suppressing inflammatory responses [88].
HDACs also play a role in neurological and inflammatory pathogenesis, particularly in alpha-synuclein
toxicity [89]. Because of their role on Lewy body formation, alpha-synuclein suppression has been an
important approach for PD and AD therapeutics [90]. SFCAs inhibit HDAC activity and can thereby
modulate alpha-synuclein pathogenicity [91].
Because of their importance as signaling and receptor molecules, enhancing SCFA availability
appears important in addressing neurodegenerative disease [92]. In that regard, the prebiotics that
include the short-chain fatty acids and bacterial products of fermentation are implicated in ASD and its
treatment [93,94]. By enhancing SCFA production through the metabolism of intestinal carbohydrates
and dietary fiber, there is the potential to affect HDAC inhibition, lower alpha-synuclein toxicity and
inhibit Lewy body accumulation. To date, there are few treatments and inadequate diagnostic tools for
diffuse Lewy body disease. Additionally, activation of GPCRs through increased SCFA availability
can contribute to reduced inflammatory responses. CRISPR modification of carbohydrate metabolic
pathways through simple changes such as ribosomal binding site (RBS) optimization can increase rates
of carbohydrate fermentation and SCFA production and have an inhibitory effect on CNS inflammation
and Lewy body formation. Additionally, CRISPRa activation of target genes can similarly increase
transcription and SCFA availability. Finally, a new synbiotic combination using probiotics with dietary
SCFA’s, fiber, high protein, and vitamin D could be a bariatric support regimen for gastric bypass and
the like.
1.11. Novel New Antibiotics and Synbiotics to Treat Diseases and Age-Related Syndromes
Probiotics and synbiotics have been proposed as potential solutions to dysbiosis and could restore
microbial balance, eventually positively affecting metabolism and signal molecule production with
respect to the gut–brain neuroendocrine axis [2,82]. Though live culture dosing offers a simple and
efficacious approach [95], new anaerobic bacterial probiotics are needed. When coupled with modern
molecular and synthetic biology techniques, particularly CRISPR, these probiotics could offers far
more powerful tools to address the bidirectional effects of neurodegenerative disease co-metabolism.
A hurdle to those of us who have considered and devised these approaches is the requirement to
label this treatment as a drug. The microbes used are within the public domain and are commonly found
in the gut of humans throughout the world. Understandably, there is a need for safety and oversight
considerations with microbes, but stringent regulations can restrict and slow the development of these
treatments, relegating them to interests that have the most money. One solution may be to create
a new oversight and regulatory agency for the rapid and safe development of these transformative
technologies for the benefit of human kind.
1.12. Ruterin as a Natural Source of Antibacterial Agent.
Ruterin is a complex mixture of glycerol-derived products, consisting of acrolein, acrolein
hydrate, 3-hydroxypropanal (3-HPA), and its dimerization product, 3-hydroxy-2-(3-hydroxypropyl)-
1,3-dioxolane among other not yet identified components [96,97]. Ruterin is a metabolic product of
glycerol and is excreted as an antibacterial agent by many symbiotic gut-bacterial species and it exerts
antibacterial effects against a broad variety of Gram-positive and Gram-negative bacteria, bacterial
spores, and also has potential antifungal effectiveness [98]. The dehydration of glycerol to generate
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3-HPA is effected by a coenzyme B12-dependent glycerol dehydratase, as established in cases of
some Lactobacillus species [99–104]. The involvement of free-radical mechanism for this dehydratase
catalyzed formation of 3-HPA was shown by ESR techniques [101,102,105].
Although, the 3-HPA is rapidly further reduced to 1,3-propanediol by 1,3-propanediol
dehydrogenase, in certain microbial species, including Lactobacillus ruteri and in Eubacterium hallii, there
is a lack in dehydrogenase activity leading to the secretion of 3-HPA by these organisms. The term
ruterin is derived from its major source of production, Lactobacillus ruteri. Ruterin exhibits antimicrobial
properties and is involved in many beneficial effects, such as cancer suppression and attenuated
inflammation. The antimicrobial properties of ruterin against Escherichia coli strains was demonstrated
by co-administration of Lactobacillus ruteri and glycerol to the bovine gastrointestinal tract, a major
reservoir of the Escherichia coli, and a possible cause of food contamination [106]. The biofilm of a
Gram-positive bacterium, Lactobacillus ruteri, on dextranomer microspheres was shown to be effective
for targeted delivery of ruterin [107].
The ruterin complex is formed through both enzymatic and nonenzymatic reactions, and its
major constituents, such as 3-HPA, are in dynamic equilibrium with other components. Abundant
evidence on the biosynthetic pathways for the formation of ruterin indicates that in initial stages,
glycerol dehydratase transforms glycerol into the 3-hydroxypropananl (3-HPA), which is in equilibrium
with acrolein that is formed through further nonenzymatic dehydration path (Figure 1). 3-HPA is
also in dynamic equilibrium with its dimeric 1,3-dioxolane product (3-HPA dimer) and with its
hydrate. The abundant quantities of 3-HPA available from the biomass would also provide a source of
value-added chemicals, possibly as alternatives to the fossil feedstocks [108].
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3-hydroxypropanal (3-HPA) dimer; and the Michael reaction of acrolein with glutathione and
imidazopyridinium compounds (PhIP), which are constituents of the ruterin-susceptible bacteria.
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The involvement of acrolein as the constituent of the ruterin system, and its direct involvement
in the decontamination of the ruterin-sensitive gut bacteria was established through a combined
experimental technique involving ion-exclusion chromatography with pulsed-amperometric detection
(IC-PAD), NMR and ultra-performance liquid chromatography–electrospray ionization mass
spectrometry (LC/ESI-MS) [96]. It is also likely that acrolein may exist in dynamic equilibrium
with a heterodimeric 1,3-dioxolane arising from its reaction with 3-HPA. Perhaps through the latter
stabilizing effect, the reactive acrolein is generated as it is needed for its reactivity with thiol antioxidants,
such as glutathione. Thus, by depleting the intracellular sources of antioxidants that would sequester the
reactive active-oxygen and reactive nitrogen species (ROS and RNS) ruterin contributes to exacerbated
oxidative stress and the resulting microbial toxicity.
Ruterin is also involved in the detoxification of the otherwise toxic heterocyclic amines, such as
imidazopyridine compounds (PhIP), which are formed as a result of the Maillard reactions of reducing
carbohydrates and amino acids or proteins. The observation of the acrolein conjugation of PhIP provides
strong evidence of the potential antibacterial effects of the acrolein component of ruterin [96,109].
Extracts of ruterin were also shown to be effective in the reducing plate counts of Enterobacteriaceae and
yeasts in minimally processed fresh lettuce [110].
2. Conclusions and Outlook
While 3-HPA not only serves as a source of the endogenously formed antibacterial agent acrolein
as shown by Lacroix et al. [96], but it is likely to stabilize acrolein through a possible acetal product
that would serve as a slow-release source of the acrolein for its antibacterial effects (Figure 1). Thus,
acrolein-3-HPA dimeric product may be an important component of the antibacterial ruterin. The latter
potential stabilizing effect of 3-HPA on the acrolein (which in relatively large concentrations is a
known carcinogen) warrants further examination. Thus, the toxicity of the ingested acrolein-rich
foods, those arising from processed foods, may be ameliorated by the gut-bacteria derived ruterin
system. Furthermore, we hypothesize that various 1,2-dicarbonyl precursors of advanced glycation
end products (AGEs) may also be in dynamic equilibrium with the 3-HPA so that 3-HPA exerts its
anti-glycating effect by sequestering the AGE-precursors.
We have used directed evolution to mutate Pseudomonas sp. after discovering this species could
metabolize diesel fuel spills [111]. This hypothesis, although not yet tested in the gut microbiota,
has proof of principle behind it and will support a possible pathway for ameliorating the toxic effects
of the exogenously consumed and endogenously formed AGEs. Similarly, one hope is that bacteria
one day can be designed to target and reverse the age-related crosslinks in tissues protein and nucleic
acids or lipids. The earliest expectation is to succeed by deglycating non-enzymatic post translational
modifications from sugars by targeting the early reversible glycation intermediates and preventing
downstream propagation and advanced end product formation [112–116]. At the same time, we
explored directed evolution and phage display technology and other engineering mechanisms, such as
inhibitors of bacterial enzymes. It is possible for phage display coupled with a kill switch to target
many bacteria and toxins or novel substrates, such as now being considered for the treatment for
cancer. Here, the phage could reach its target and carry with it a wavelength-specific light-activated
killing mechanism which can be both target and a treatment. In summary, when one considers the
prospects of the microbiota and mycobiota as a transformative force for change against the hype that
may come with expectation both perspectives have a hydraulic effect on the international scientific
system and community. As eternal optimist’s we hope to have objectively argued for transformative
properties of the microbiota and mycobiota.
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Appendix A
Table A1. Mycobiome Species and Significance.
Category Fungal Species Significance
Infant GI/Skin
Mother to infant
Candida (breast (breastmilk), skin, oral, vaginal/birth and GI)















C. parapsilosis, C. tropicalis, C. albicans, C. orthopsilosis
(birth mode, oral, environment), C. quercitrusa,
C. diddensiae, C. krusei, C. guilliermondii, C. geocandidum
Saccharomyces cerevisiae (infant GI)
Saccharomycetales (overgrowth)
Cryptococcus pseudolongus (C. albidosimilas and C. podzolicus)
Cladosporium velox (C. sphaerospermum and C. tenuissimum)
(body site)
Debaryomyces renaii (body site)
D. hansenii(body site)
Hanseniaspora uvarum (body site)























Infant skin Malassezia Colonizer/pathogenic
Infant oral
mycobiome
Candida species such as C. albicans, C. parapsilosis, C. krusei,
















Pathogenic fungi Saccharomyces, Candida, Aspergillus, Malassezia, Penicillium AllergyDisseminated infection
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Table A2. Shift in the most dominant phyla of gut bacteria across the human lifespan.
Age Range Most Prevalent Phyla Common Genera
Infancy 0–3 years
Actinobacteria Propionibacterium, Rothia, Actinomyces,Bifidobacterium, Collinsella, Eggerthella, Mobiluncus
Proteobacteria Escherichia, Shigella, Aggregatibacter, Eikenella
Firmicutes
Enterococcus, Gemella, Staphylococcus, Streptococcus,
Anaerococcus, Granulicatella, Lactobacillus,
Peptoniphilus, Veillonella, Anaerostipes, Anaerotruncus,





Enterococcus, Gemella, Staphylococcus, Streptococcus,
Anaerococcus, Granulicatella, Lactobacillus,
Peptoniphilus, Veillonella, Anaerostipes, Anaerotruncus,
Costridium, Megasphaera, Roseburia, Ruminococcus
Bacteroidetes Bacteroides
Actinobacteria Propionibacterium, Rothia, Actinomyces,Bifidobacterium, Collinsella, Eggerthella, Mobiluncus
Proteobacteria Escherichia, Shigella, Aggregatibacter, Eikenella
Verrucomicrobia Akkkermansia
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Table A2. Cont.
Age Range Most Prevalent Phyla Common Genera
Elderly 70 years and older
Firmicutes
Enterococcus, Gemella, Staphylococcus, Streptococcus,
Anaerococcus, Granulicatella, Lactobacillus,
Peptoniphilus, Veillonella, Anaerostipes, Anaerotruncus,
Costridium, Megasphaera, Roseburia, Ruminococcus
Actinobacteria Propionibacterium, Rothia, Actinomyces,Bifidobacterium, Collinsella, Eggerthella, Mobiluncus
Bacteroidetes Bacteroides
Proteobacteria Escherichia, Shigella, Aggregatibacter, Eikenella
Verrucomicrobia Akkermansia
Table of Microbiome: Depiction of the shift in gut flora across the human life span. The most prevalent phyla column
for each age range is ordered from most prevalent to lower levels of prevalence. The common genera depicted for
each phyla does not represent all members of the gut flora, however, it represents the most prevalent organisms
populating the gut [117–119].
References
1. Obrenovich, M. Leaky Gut, Leaky Brain? Microorganisms 2018, 6, 107. [CrossRef]
2. Obrenovich, M.; Rai, H.; Mana, T.S.; Shola, D.; McCloskey, B. Dietary Co-Metabolism within the
Microbiota-Gut-Brain-Endocrine Metabolic Interactome. BAO Microbiol. 2017, 2, 22.
3. Ward, T.L.; Knights, D.; Gale, C.A. Infant fungal communities: Current knowledge and research opportunities.
BMC Med. 2017, 15, 30. [CrossRef]
4. Ward, T.L.; Dominguez-Bello, M.G.; Heisel, T.; Al-Ghalith, G.; Knights, D.; Gale, C.A. Development of
the Human Mycobiome over the First Month of Life and across Body Sites. MSystems 2018, 3, e00140-17.
[CrossRef]
5. Gareau, M.G. Microbiota-gut-brain axis and cognitive function. In Microbial Endocrinology: The Microbiota-Gut-Brain
Axis in Health and Disease; Mark, L., John, C., Eds.; Springer: New York, NY, USA, 2014; pp. 357–371.
6. Obrenovich, M.; Flückiger, R.; Sykes, L.; Donskey, C. The co-metabolism within the gut-brain metabolic
interaction: Potential targets for drug treatment and design. CNS Neurol. Disord. Drug Targets 2016,
15, 127–134. [CrossRef]
7. Matsuzaki, S.; Rashel, M.; Uchiyama, J.; Sakurai, S.; Ujihara, T.; Kuroda, M.; Ikeuchi, M.; Tani, T.; Fujieda, M.;
Wakiguchi, H.; et al. Bacteriophage therapy: A revitalized therapy against bacterial infectious diseases.
J. Infect. Chemother. 2005, 11, 211–219. [CrossRef] [PubMed]
8. Koenig, J.E.; Spor, A.; Scalfone, N.; Fricker, A.D.; Stombaugh, J.; Knight, R.; Angenent, L.T.; Ley, R.E.
Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl. Acad. Sci. USA 2011,
108, 4578–4585. [CrossRef]
9. Biagi, E.; Nylund, L.; Candela, M.; Ostan, R.; Bucci, L.; Pini, E.; Nikkïla, J.; Monti, D.; Satokari, R.; Franceschi, C.;
et al. Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians.
PLoS ONE 2010, 5, e10667. [CrossRef]
10. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.;
Yamada, T.; et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature
2010, 464, 59. [CrossRef] [PubMed]
11. Dominguez-Bello, M.G.; Blaser, M.J.; Ley, R.E.; Knight, R. Development of the human gastrointestinal
microbiota and insights from high-throughput sequencing. Gastroenterology 2011, 140, 1713–1719. [CrossRef]
[PubMed]
12. Groschwitz, K.R.; Hogan, S.P. Intestinal barrier function: Molecular regulation and disease pathogenesis.
J. Allergy Clin. Immunol. 2009, 124, 3–20. [CrossRef] [PubMed]
13. Alberts, B. Molecular Biology of the Cell, 6th ed.; Garland Science, Taylor and Francis Group: New York, NY,
USA, 2015; ISBN 978-0-8153-4432-2.
14. Daneman, R.; Prat, A. The blood-brain barrier. Cold Spring Harb. Perspect. Biol. 2015, 7, a020412. [CrossRef]
[PubMed]
Biomedicines 2019, 7, 24 17 of 21
15. Nation, D.A.; Sweeney, M.D.; Montagne, A.; Sagare, A.P.; D’Orazio, L.M.; Pachicano, M.; Sepehrband, F.;
Nelson, A.R.; Buennagel, D.P.; Harrington, M.G.; et al. Blood–brain barrier breakdown is an early biomarker
of human cognitive dysfunction. Nat. Med. 2019, 25, 270–276. [CrossRef] [PubMed]
16. Rogers, G.B.; Keating, D.J.; Young, R.L.; Wong, M.L.; Licinio, J.; Wesselingh, S. From gut dysbiosis to altered
brain function and mental illness: Mechanisms and pathways. Mol. Psychiatry 2016, 21, 738–748. [CrossRef]
[PubMed]
17. Paharik, A.E.; Schreiber, H.L.; Spaulding, C.N.; Dodson, K.W.; Hultgren, S.J. Narrowing the spectrum:
The new frontier of precision antimicrobials. Genome Med. 2017, 9, 110. [CrossRef]
18. Braundmeier, A.G.; Lenz, K.M.; Inman, K.S.; Chia, N.; Jeraldo, P.; Walther-António, M.R.; Berg Miller, M.E.;
Yang, F.; Creedon, D.J.; Nelson, H.; et al. Individualized medicine and the microbiome in reproductive tract.
Front. Physiol. 2015, 6, 97. [CrossRef]
19. Nash, A.K.; Auchtung, T.A.; Wong, M.C.; Smith, D.P.; Gesell, J.R.; Ross, M.C.; Stewart, C.J.; Metcalf, G.A.;
Muzny, D.M.; Gibbs, R.A.; et al. The gut mycobiome of the Human Microbiome Project healthy cohort.
Microbiome 2017, 5, 153. [CrossRef] [PubMed]
20. Forbes, J.D.; Bernstein, C.N.; Tremlett, H.; Van Domselaar, G.; Knox, N.C. A Fungal World: Could the Gut
Mycobiome Be Involved in Neurological Disease? Front. Microbiol. 2019, 9, 3249. [CrossRef]
21. Sogin, M.L.; Morrison, H.G.; Huber, J.A.; Welch, D.M.; Huse, S.M.; Neal, P.R.; Arrieta, J.M.; Herndl, G.J.
Microbial diversity in the deep sea and the underexplored “rare biosphere”. Proc. Natl. Acad. Sci. USA 2006,
103, 12115–12120. [CrossRef]
22. Peleg, A.Y.; Hogan, D.A.; Mylonakis, E. Medically important bacterial–fungal interactions. Nat. Rev. Microbiol.
2010, 8, 340. [CrossRef]
23. Drell, T.; Lillsaar, T.; Tummeleht, L.; Simm, J.; Aaspõllu, A.; Väin, E.; Saarma, I.; Salumets, A.; Donders, G.G.;
Metsis, M. Characterization of the vaginal micro-and mycobiome in asymptomatic reproductive-age Estonian
women. PLoS ONE 2013, 8, e54379. [CrossRef]
24. Rozovsky, I.; Finch, C.E.; Morgan, T.E. Age-related activation of microglia and astrocytes: In vitro studies show
persistent phenotypes of aging, increased proliferation, and resistance to down-regulation. Neurobiol. Aging
1998, 19, 97–103. [CrossRef]
25. Wu, Y.; Du, S.; Johnson, J.L.; Tung, H.Y.; Landers, C.T.; Liu, Y.; Seman, B.G.; Wheeler, R.T.; Costa-Mattioli, M.;
Kheradmand, F.; et al. Microglia and amyloid precursor protein coordinate control of transient Candida
cerebritis with memory deficits. Nat. Commun. 2019, 10, 58. [CrossRef]
26. Ghannoum, M.A.; Jurevic, R.J.; Mukherjee, P.K.; Cui, F.; Sikaroodi, M.; Naqvi, A.; Gillevet, P.M.
Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog. 2010,
6, e1000713. [CrossRef]
27. Charlson, E.S.; Diamond, J.M.; Bittinger, K.; Fitzgerald, A.S.; Yadav, A.; Haas, A.R.; Bushman, F.D.;
Collman, R.G. Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung
transplant. Am. J. Respir. Crit. Care Med. 2012, 186, 536–545. [CrossRef]
28. Seed, P.C. The human mycobiome. Cold Spring Harb. Perspect. Med. 2015, 5, a019810. [CrossRef]
29. Bradford, L.L.; Ravel, J. The vaginal mycobiome: A contemporary perspective on fungi in women’s health
and diseases. Virulence 2016, 8, 342–351. [CrossRef]
30. Sam, Q.H.; Chang, M.W.; Chai, L.Y. The Fungal Mycobiome and Its Interaction with Gut Bacteria in the Host.
Int. J. Mol. Sci. 2017, 18, 330. [CrossRef]
31. Huffnagle, G.B.; Noverr, M.C. The emerging world of the fungal microbiome. Trends Microbiol. 2013,
21, 334–341. [CrossRef]
32. Butel, M.J.; Waligora-Dupriet, A.J.; Wydau-Dematteis, S. The developing gut microbiota and its consequences
for health. J. Dev. Orig. Health Dis. 2018, 9, 590–597. [CrossRef]
33. Aagaard, K.; Ma, J.; Antony, K.M.; Ganu, R.; Petrosino, J.; Versalovic, J. The placenta harbors a unique
microbiome. Sci. Transl. Med. 2014, 6, 237ra65. [CrossRef]
34. Thum, C.; Cookson, A.L.; Otter, D.E.; McNabb, W.C.; Hodgkinson, A.J.; Dyer, J.; Roy, N.C. Can Nutritional
Modulation of Maternal Intestinal Microbiota Influence the Development of the Infant Gastrointestinal Tract?
J. Nutr. 2012, 142, 1921–1928. [CrossRef]
35. Neu, J. Developmental aspects of maternal-fetal, and infant gut microbiota and implications for long-term
health. Matern. Health Neonatol. Perinatol. 2015, 1, 6. [CrossRef]
Biomedicines 2019, 7, 24 18 of 21
36. Jeurink, P.V.; Van Bergenhenegouwen, J.; Jimenez, E.; Knippels, L.M.; Fernández, L.; Garssen, J.; Knol, J.;
Rodriguez, J.M.; Martin, R. Human milk: A source of more life than we imagine. Benef. Microbes 2012,
4, 17–30. [CrossRef]
37. Hunt, K.M.; Foster, J.A.; Forney, L.J.; Schütte, U.M.; Beck, D.L.; Abdo, Z.; Fox, L.K.; Williams, J.E.;
McGuire, M.K.; McGuire, M.A. Characterization of the diversity and temporal stability of bacterial
communities in human milk. PLoS ONE 2011, 6, e21313. [CrossRef]
38. Biagi, E.; Candela, M.; Fairweather-Tait, S.; Franceschi, C.; Brigidi, P. Ageing of the human metaorganism:
The microbial counterpart. Age 2012, 34, 247–267. [CrossRef]
39. Palmer, C.; Bik, E.M.; DiGiulio, D.B.; Relman, D.A.; Brown, P.O. Development of the human infant intestinal
microbiota. PLoS Biol. 2007, 5, e177. [CrossRef]
40. Bale, T.L.; Baram, T.Z.; Brown, A.S.; Goldstein, J.M.; Insel, T.R.; McCarthy, M.M.; Nemeroff, C.B.; Reyes, T.M.;
Simerly, R.B.; Susser, E.S.; et al. Early life programming and neurodevelopmental disorders. Biol. Psychiatry
2010, 68, 314–319. [CrossRef]
41. Hsiao, E.Y.; McBride, S.W.; Hsien, S.; Sharon, G.; Hyde, E.R.; McCue, T.; Codelli, J.A.; Chow, J.; Reisman, S.E.;
Petrosino, J.F.; et al. Microbiota modulate behavioral and physiological abnormalities associated with
neurodevelopmental disorders. Cell 2013, 155, 1451–1463. [CrossRef]
42. Obrenovich, M.E.; Shola, D.; Schroedel, K.; Agrahari, A.; Lonsdale, D. The role of trace elements, thiamin (e)
in autism and autistic spectrum disorder. Front. Biosci. 2015, 7, 263–277.
43. Mittal, V.A.; Ellman, L.M.; Cannon, T.D. Gene-environment interaction and covariation in schizophrenia:
The role of obstetric complications. Schizophr. Bull. 2008, 34, 1083–1094. [CrossRef] [PubMed]
44. Thompson, B.L.; Levitt, P.; Stanwood, G.D. Prenatal exposure to drugs: Effects on brain development and
implications for policy and education. Nat. Rev. Neurosci. 2009, 10, 303. [CrossRef] [PubMed]
45. Ben-Ari, Y. Neuropaediatric and neuroarchaeology: Understanding development to correct brain disorders.
Acta Paediatr. 2013, 102, 331–334. [CrossRef] [PubMed]
46. Finegold, S.M. State of the art; microbiology in health and disease. Intestinal bacterial flora in autism.
Anaerobe 2011, 17, 367–368. [CrossRef] [PubMed]
47. Sun, W.; Poschmann, J.; del Rosario, R.C.; Parikshak, N.N.; Hajan, H.S.; Kumar, V.; Ramasamy, R.; Belgard, T.G.;
Elanggovan, B.; Wong, C.C.; et al. Histone acetylome-wide association study of autism spectrum disorder.
Cell 2016, 167, 1385–1397. [CrossRef] [PubMed]
48. Mulle, J.G.; Sharp, W.G.; Cubells, J.F. The gut microbiome: A new frontier in autism research.
Curr. Psychiatry Rep. 2013, 15, 337. [CrossRef] [PubMed]
49. Rapoport, J.L.; Giedd, J.N.; Gogtay, N. Neurodevelopmental model of schizophrenia: Update 2012.
Mol. Psychiatry 2012, 17, 1228. [CrossRef]
50. Shaw, W. Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA),
an abnormal phenylalanine metabolite of Clostridia spp. in the gastrointestinal tract, in urine samples from
patients with autism and schizophrenia. Nutr. Neurosci. 2010, 13, 135–143. [CrossRef]
51. Ming, X.; Stein, T.P.; Barnes, V.; Rhodes, N.; Guo, L. Metabolic perturbance in autism spectrum disorders:
A metabolomics study. J. Proteome Res. 2012, 11, 5856–5862. [CrossRef]
52. Obrenovich, M.E.; Donskey, C.J.; Schiefer, I.T.; Bongiovanni, R.; Li, L.; Jaskiw, G.E. Quantification of phenolic
acid metabolites in humans by LC–MS: A structural and targeted metabolomics approach. Bioanalysis 2018,
10, 1591–1608. [CrossRef]
53. De Theije, C.G.; Wopereis, H.; Ramadan, M.; van Eijndthoven, T.; Lambert, J.; Knol, J.; Garssen, J.;
Kraneveld, A.D.; Oozeer, R. Altered gut microbiota and activity in a murine model of autism spectrum
disorders. Brain Behav. Immun. 2014, 37, 197–206. [CrossRef]
54. Douglas-Escobar, M.; Elliott, E.; Neu, J. Effect of intestinal microbial ecology on the developing brain.
JAMA Pediatr. 2013, 167, 374–379. [CrossRef] [PubMed]
55. Desbonnet, L.; Clarke, G.; Shanahan, F.; Dinan, T.G.; Cryan, J.F. Microbiota is essential for social development
in the mouse. Mol. Psychiatry 2014, 19, 146. [CrossRef] [PubMed]
56. Iversen, L. Neurotransmitter transporters: Fruitful targets for CNS drug discovery. Mol. Psychiatry 2000,
5, 357. [CrossRef] [PubMed]
57. Wall, R.; Cryan, J.F.; Ross, R.P.; Fitzgerald, G.F.; Dinan, T.G.; Stanton, C. Bacterial neuroactive compounds
produced by psychobiotics. In Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease;
Mark, L., John, C., Eds.; Springer: New York, NY, USA, 2014; pp. 221–239.
Biomedicines 2019, 7, 24 19 of 21
58. Zhou, L.; Foster, J.A. Psychobiotics and the gut–brain axis: In the pursuit of happiness. Neuropsychiatr. Dis. Treat.
2015, 11, 715.
59. David, L.A.; Maurice, C.F.; Carmody, R.N.; Gootenberg, D.B.; Button, J.E.; Wolfe, B.E.; Ling, A.V.; Devlin, A.S.;
Varma, Y.; Fischbach, M.A.; et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature
2014, 505, 559. [CrossRef]
60. Claesson, M.J.; Cusack, S.; O’Sullivan, O.; Greene-Diniz, R.; de Weerd, H.; Flannery, E.; Marchesi, J.R.;
Falush, D.; Dinan, T.; Fitzgerald, G.; et al. Composition, variability, and temporal stability of the intestinal
microbiota of the elderly. Proc. Natl. Acad. Sci. USA 2011, 108, 4586–4591. [CrossRef]
61. Ostan, R.; Bucci, L.; Capri, M.; Salvioli, S.; Scurti, M.; Pini, E.; Monti, D.; Franceschi, C. Immunosenescence
and immunogenetics of human longevity. Neuroimmunomodulation 2008, 15, 224–240. [CrossRef]
62. Biagi, E.; Candela, M.; Turroni, S.; Garagnani, P.; Franceschi, C.; Brigidi, P. Ageing and gut microbes:
Perspectives for health maintenance and longevity. Pharmacol. Res. 2013, 69, 11–20. [CrossRef]
63. Carter, C.J. Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier
Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease. J. Alzheimer’s
Dis. Rep. 2017, 1, 125–157. [CrossRef]
64. Seidel, J.; Valenzano, D.R. The role of the gut microbiome during host ageing. F1000Research 2018, 7.
[CrossRef]
65. Winek, K.; Dirnagl, U.; Meisel, A. The gut microbiome as therapeutic target in central nervous system
diseases: Implications for stroke. Neurotherapeutics 2016, 13, 762–774. [CrossRef]
66. Smith, P.; Willemsen, D.; Popkes, M.; Metge, F.; Gandiwa, E.; Reichard, M.; Valenzano, D.R. Regulation of life
span by the gut microbiota in the short-lived African turquoise killifish. Elife 2017, 6, e27014. [CrossRef]
67. Hecker, M.T.; Obrenovich, M.E.; Cadnum, J.L.; Jencson, A.L.; Jain, A.K.; Ho, E.; Donskey, C.J. Fecal microbiota
transplantation by freeze-dried oral capsules for recurrent Clostridium difficile infection. In Open Forum
Infectious Diseases; Oxford University Press: Oxford, UK, 2016; Volume 3.
68. Conboy, I.M.; Conboy, M.J.; Wagers, A.J.; Girma, E.R.; Weissman, I.L.; Rando, T.A. Rejuvenation of aged
progenitor cells by exposure to a young systemic environment. Nature 2005, 433, 760. [CrossRef]
69. Mccay, C.M.; Pope, F.; Lunsford, W.; Sperling, G.; Sambhavaphol, P. Parabiosis between old and young rats.
Gerontology 1957, 1, 7–17. [CrossRef]
70. Ludwig, F.C.; Elashoff, R.M. Mortality in syngeneic rat parabionts of different chronological age. Trans. N. Y.
Acad. Sci. 1972, 34, 582–587. [CrossRef]
71. Pesheva, E. Critical Step Found in DNA Repair, Cellular Aging, HMS Communications; The Harvard Gazette,
2017. Available online: https://news.harvard.edu/gazette/story/2017/03/harvard-scientists-pinpoint-critical-
step-in-dna-repair-cellular-aging/ (accessed on 1 January 2019).
72. Boukaba, A.; Sanchis-Gomar, F.; García-Giménez, J.L. Epigenetic Mechanisms as Key Regulators in Disease:
Clinical Implications. Epigenetic Biomarkers and Diagnostics; Academic Press: Cambridge, MA, USA, 2016;
pp. 37–66.
73. Hoffmann, G.F.; Kölker, S. Defects of methionine and homocysteine metabolism. In Pediatric Neurology
Part III in Handbook of Clinical Neurology; Olivier, D., Maryse, L., Harvey, S., Eds.; Elsevier: Amsterdam,
The Netherlands, 2013; pp. 1755–1773.
74. De Magalhães, J.P. The scientific quest for lasting youth: Prospects for curing aging. Rejuvenation Res. 2014,
17, 458–467. [CrossRef]
75. Weil, A.A.; Hohmann, E.L. Fecal microbiota transplant: Benefits and risks. In Open Forum Infectious Diseases;
Oxford University Press: Oxford, UK, 2015; Volume 2.
76. Tsukumo, D.M.; Carvalho, B.M.; Carvalho Filho, M.A.; Saad, M.J. Translational research into gut microbiota:
New horizons on obesity treatment: Updated 2014. Arch. Endocrinol. Metab. 2015, 59, 154–160. [CrossRef]
[PubMed]
77. Candela, M.; Maccaferri, S.; Turroni, S.; Carnevali, P.; Brigidi, P. Functional intestinal microbiome, new
frontiers in prebiotic design. Int. J. Food Microbiol. 2010, 140, 93–101. [CrossRef]
78. Gaj, T.; Gersbach, C.A.; Barbas, C.F., III. ZFN, TALEN, and CRISPR/Cas-based methods for genome
engineering. Trends Biotechnol. 2013, 31, 397–405. [CrossRef]
79. Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraffini, L.; et al.
Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339, 819–823. [CrossRef]
Biomedicines 2019, 7, 24 20 of 21
80. Mali, P.; Yang, L.; Esvelt, K.M.; Aach, J.; Guell, M.; DiCarlo, J.E.; Norville, J.E.; Church, G.M. RNA-guided
human genome engineering via Cas9. Science 2013, 339, 823–826. [CrossRef] [PubMed]
81. Sonnenburg, E.D.; Smits, S.A.; Tikhonov, M.; Higginbottom, S.K.; Wingreen, N.S.; Sonnenburg, J.L.
Diet-induced extinctions in the gut microbiota compound over generations. Nature 2016, 529, 212. [CrossRef]
[PubMed]
82. Ji, W.; Lee, D.; Wong, E.; Dadlani, P.; Dinh, D.; Huang, V.; Kearns, K.; Teng, S.; Chen, S.; Haliburton, J.; et al.
Specific gene repression by CRISPRi system transferred through bacterial conjugation. ACS Synth. Biol. 2014,
3, 929–931. [CrossRef]
83. Zuberi, A.; Misba, L.; Khan, A.U. CRISPR Interference (CRISPRi) inhibition of luxS gene expression in E. coli:
An approach to inhibit biofilm. Front. Cell. Infect. Microbiol. 2017, 7, 214. [CrossRef] [PubMed]
84. Ghaisas, S.; Maher, J.; Kanthasamy, A. Gut microbiome in health and disease: Linking the
microbiome–gut–brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative
diseases. Pharmacol. Ther. 2016, 158, 52–62. [CrossRef]
85. Wu, S.C.; Cao, Z.S.; Chang, K.M.; Juang, J.L. Intestinal microbial dysbiosis aggravates the progression of
Alzheimer’s disease in Drosophila. Nat. Commun. 2017, 8, 24. [CrossRef] [PubMed]
86. Minato, T.; Maeda, T.; Fujisawa, Y.; Tsuji, H.; Nomoto, K.; Ohno, K.; Hirayama, M. Progression of Parkinson’s
disease is associated with gut dysbiosis: Two-year follow-up study. PLoS ONE 2017, 12, e0187307. [CrossRef]
[PubMed]
87. Spielman, L.J.; Gibson, D.L.; Klegeris, A. Unhealthy gut, unhealthy brain: The role of the intestinal microbiota
in neurodegenerative diseases. Neurochem. Int. 2018, 120, 149–163. [CrossRef]
88. Obrenovich, M.E.; Smith, M.A.; Siedlak, S.L.; Chen, S.G.; Jack, C.; Perry, G.; Aliev, G. Overexpression of GRK2
in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial
lesions. Neurotox. Res. 2006, 10, 43–56. [CrossRef]
89. Huang, Y.; Todd, N.; Thathiah, A. The role of GPCRs in neurodegenerative diseases: Avenues for therapeutic
intervention. Curr. Opin. Pharmacol. 2017, 32, 96–110. [CrossRef]
90. Sun, M.; Wu, W.; Liu, Z.; Cong, Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory
bowel diseases. J. Gastroenterol. 2017, 52, 1–8. [CrossRef] [PubMed]
91. Yuille, S.; Reichardt, N.; Panda, S.; Dunbar, H.; Mulder, I.E. Human gut bacteria as potent class I histone
deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS ONE 2018,
13, e0201073. [CrossRef] [PubMed]
92. Auluck, P.K.; Chan, H.E.; Trojanowski, J.Q.; Lee, V.M.; Bonini, N.M. Chaperone suppression of α-synuclein
toxicity in a Drosophila model for Parkinson’s disease. Science 2002, 295, 865–868. [CrossRef]
93. Jansen, M.S.; Nagel, S.C.; Miranda, P.J.; Lobenhofer, E.K.; Afshari, C.A.; McDonnell, D.P. Short-chain fatty
acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone
deacetylase inhibition. Proc. Natl. Acad. Sci. USA 2004, 101, 7199–7204. [CrossRef]
94. Ho, L.; Ono, K.; Tsuji, M.; Mazzola, P.; Singh, R.; Pasinetti, G.M. Protective roles of intestinal microbiota
derived short chain fatty acids in Alzheimer’s disease-type beta-amyloid neuropathological mechanisms.
Expert Rev. Neurother. 2018, 18, 83–90. [CrossRef] [PubMed]
95. MacFabe, D.F. Short-chain fatty acid fermentation products of the gut microbiome: Implications in autism
spectrum disorders. Microb. Ecol. Health Dis. 2012, 23, 19260. [CrossRef]
96. Karaki, S.I.; Tazoe, H.; Hayashi, H.; Kashiwabara, H.; Tooyama, K.; Suzuki, Y.; Kuwahara, A. Expression of
the short-chain fatty acid receptor, GPR43, in the human colon. J. Mol. Histol. 2008, 39, 135–142. [CrossRef]
97. Wang, H.; Lee, I.S.; Braun, C.; Enck, P. Effect of probiotics on central nervous system functions in animals
and humans: A systematic review. J. Neurogastroenterol. Motil. 2016, 22, 589. [CrossRef]
98. Engels, C.; Schwab, C.; Zhang, J.; Stevens, M.J.; Bieri, C.; Ebert, M.O.; McNeill, K.; Sturla, S.J.; Lacroix, C.
Acrolein contributes strongly to antimicrobial and heterocyclic amine transformation activities of reuterin.
Sci. Rep. 2016, 6, 36246. [CrossRef]
99. Zhang, J.; Sturla, S.; Lacroix, C.; Schwab, C. Gut Microbial Glycerol Metabolism as an Endogenous Acrolein
Source. MBio 2018, 9, e01947-17. [CrossRef]
100. Vimont, A.; Fernandez, B.; Ahmed, G.; Fortin, H.P.; Fliss, I. Quantitative antifungal activity of reuterin
against food isolates of yeasts and moulds and its potential application in yogurt. Int. J. Food Microbiol. 2019,
289, 182–188. [CrossRef]
Biomedicines 2019, 7, 24 21 of 21
101. Talarico, T.L.; Dobrogosz, W.J. Purification and characterization of glycerol dehydratase from Lactobacillus
reuteri. Appl. Environ. Microbiol. 1990, 56, 1195–1197.
102. Toraya, T.; Eda, M.; Kamachi, T.; Yoshizawa, K. Energetic feasibility of hydrogen abstraction and recombination
in coenzyme B12-dependent diol dehydratase reaction. J. Biochem. 2001, 130, 865–872. [CrossRef]
103. Toraya, T. Radical catalysis in coenzyme B12-dependent isomerization (eliminating) reactions. Chem. Rev.
2003, 103, 2095–2128. [CrossRef]
104. Frey, P.A.; Reed, G.H. Radical mechanisms in adenosylmethionine-and adenosylcobalamin-dependent
enzymatic reactions. Arch. Biochem. Biophys. 2000, 382, 6–14. [CrossRef]
105. Shibata, N.; Nakanishi, Y.; Fukuoka, M.; Yamanishi, M.; Yasuoka, N.; Toraya, T. Structural rationalization
for the lack of stereospecificity in coenzyme B12-dependent diol dehydratase. J. Biol. Chem. 2003,
278, 22717–22725. [CrossRef]
106. Knietsch, A.; Bowien, S.; Whited, G.; Gottschalk, G.; Daniel, R. Identification and characterization of
coenzyme B12-dependent glycerol dehydratase-and diol dehydratase-encoding genes from metagenomic
DNA libraries derived from enrichment cultures. Appl. Environ. Microbiol. 2003, 69, 3048–3060. [CrossRef]
107. Finlay, T.H.; Valinsky, J.; Mildvan, A.S.; Abeles, R.H. Electron Spin Resonance Studies with Dioldehydrase
Evidence for Radical Intermediates in reactions catalyzed by Coenzyme B12. J. Biol. Chem. 1973,
248, 1285–1290.
108. Bertin, Y.; Habouzit, C.; Dunière, L.; Laurier, M.; Durand, A.; Duchez, D.; Segura, A.; Thévenot-Sergentet, D.;
Baruzzi, F.; Chaucheyras-Durand, F.; et al. Lactobacillus reuteri suppresses E. coli O157: H7 in bovine ruminal
fluid: Toward a pre-slaughter strategy to improve food safety? PLoS ONE 2017, 12, e0187229. [CrossRef]
109. Navarro, J.B.; Mashburn-Warren, L.; Bakaletz, L.O.; Bailey, M.T.; Goodman, S.D. Enhanced probiotic potential
of Lactobacillus reuteri when delivered as a biofilm on dextranomer microspheres that contain beneficial
cargo. Front. Microbiol. 2017, 8, 489. [CrossRef]
110. De Fouchécour, F.; Sánchez-Castañeda, A.K.; Saulou-Bérion, C.; Spinnler, H.É. Process engineering for
microbial production of 3-hydroxypropionic acid. Biotechnol. Adv. 2018, 36, 1207–1222. [CrossRef]
111. Zhang, J.; Empl, M.T.; Schwab, C.; Fekry, M.I.; Engels, C.; Schneider, M.; Lacroix, C.; Steinberg, P.; Sturla, S.J.
Gut microbial transformation of the dietary imidazoquinoxaline mutagen MelQx reduces its cytotoxic and
mutagenic potency. Toxicol. Sci. 2017, 159, 266–276. [CrossRef]
112. Asare, P.T.; Greppi, A.; Stettler, M.; Schwab, C.; Stevens, M.J.; Lacroix, C. Decontamination of
minimally-processed fresh lettuce using reuterin produced by Lactobacillus reuteri. Front. Microbiol. 2018,
9, 1421. [CrossRef]
113. Van Hamme, J.D.; Singh, A.; Ward, O.P. Recent Advances in Petroleum Microbiology. Microbiol. Mol. Biol. Rev.
2003, 67, 503–549. [CrossRef]
114. Troise, A.D.; Buonanno, M.; Fiore, A.; Monti, S.M.; Fogliano, V. Evolution of protein bound Maillard reaction
end-products and free Amadori compounds in low lactose milk in presence of fructosamine oxidase I.
Food Chem. 2016, 212, 722–729. [CrossRef]
115. Qian, Y.; Zheng, J.; Lin, Z. Loop engineering of amadoriase II and mutational cooperativity. Appl. Microbiol.
Biotechnol. 2013, 97, 8599–8607. [CrossRef]
116. Collard, F.; Fagan, R.L.; Zhang, J.; Nemet, I.; Palfey, B.A.; Monnier, V.M. The Cation—pi Interaction between
Lys53 and the Flavin of Fructosamine Oxidase (FAOX-II) Is Critical for Activity. Biochemistry 2011, 50,
7977–7986. [CrossRef]
117. Backhed, F.; Roswall, J.; Peng, Y.; Feng, Q.; Jia, H.; Kovatcheva-Datchary, P.; Li, Y.; Xia, Y.; Xie, H.; Zhong, H.;
et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe
2015, 17, 690–703. [CrossRef]
118. D’Argenio, V.; Salvatore, F. The role of the gut microbiome in the healthy adult status. Clin. Chim. Acta 2015,
451, 97–102. [CrossRef]
119. Naito, Y.; Uchiyama, K.; Takagi, T. A next generation beneficial microbe: Akkermansia Muciniphilia. J. Clin.
Biochem. Nutr. 2018, 63, 33–35.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
